BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23625935)

  • 1. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
    Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
    Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
    Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
    Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
    Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
    Elife; 2016 May; 5():. PubMed ID: 27244239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
    Ravindra KC; Selvi BR; Arif M; Reddy BA; Thanuja GR; Agrawal S; Pradhan SK; Nagashayana N; Dasgupta D; Kundu TK
    J Biol Chem; 2009 Sep; 284(36):24453-64. PubMed ID: 19570987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.
    Stimson L; Rowlands MG; Newbatt YM; Smith NF; Raynaud FI; Rogers P; Bavetsias V; Gorsuch S; Jarman M; Bannister A; Kouzarides T; McDonald E; Workman P; Aherne GW
    Mol Cancer Ther; 2005 Oct; 4(10):1521-32. PubMed ID: 16227401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening.
    Xiong H; Han J; Wang J; Lu W; Wang C; Chen Y; Fulin Lian ; Zhang N; Liu YC; Zhang C; Ding H; Jiang H; Lu W; Luo C; Zhou B
    Eur J Med Chem; 2018 May; 151():740-751. PubMed ID: 29665527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
    Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
    Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
    Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
    Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
    Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
    Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies.
    Abulkhair HS; Turky A; Ghiaty A; Ahmed HEA; Bayoumi AH
    Bioorg Chem; 2020 Jul; 100():103899. PubMed ID: 32454390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP.
    Wurm T; Wright DG; Polakowski N; Mesnard JM; Lemasson I
    Nucleic Acids Res; 2012 Jul; 40(13):5910-25. PubMed ID: 22434882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of small-molecule inhibitors of lysine acetyltransferases.
    Liao D
    Methods Mol Biol; 2015; 1238():539-48. PubMed ID: 25421679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
    Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
    Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
    Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
    Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.